NIMG-32. POSTPROGRESSION SURVIVAL AND MRI FEATURES AT PROGRESSION IN MGMT-METHYLATED GLIOBLASTOMA FOLLOWING TEMOZOLOMIDE (TMZ) OR CCNU/TMZ THERAPY - AN ANALYSIS OF THE CETEG/NOA-09-TRIAL

Authors: Thomas Zeyen, Daniel Paech, Johannes Weller, Niklas Schäfer, Theophilos Tzaridis, Cathrina Duffy, Louisa Nitsch, Matthias Schneider, Joachim Steinbach, Peter Hau, Uwe Schlegel, Clemens Seidel, Dietmar Krex, Oliver Grauer, Roland Goldbrunner, Pia Zeiner, Ghazaleh Tabatabai, Norbert Galldiks, Walter Stummer, Elke Hattingen, Martin Glas, Alexander Radbruch, Ulrich Herrlinger, Christina Schaub

Published: 2022-11-14

DOI: 10.1093/neuonc/noac209.650

Source: Full article

NIMG-32. POSTPROGRESSION SURVIVAL AND MRI FEATURES AT PROGRESSION IN MGMT-METHYLATED GLIOBLASTOMA FOLLOWING TEMOZOLOMIDE (TMZ) OR CCNU/TMZ THERAPY - AN ANALYSIS OF THE CETEG/NOA-09-TRIAL

Abstract